Information Provided By:
Fly News Breaks for October 28, 2016
SNY, REGN
Oct 28, 2016 | 10:08 EDT
Piper Jaffray analyst Edward Tenthoff attributes the weakness in shares of Regeneron Pharmaceuticals (REGN) to the FDA alerting Sanofi (SNY) of fill-finish manufacturing deficiencies for certain products including sarilumab. Sarilumab is an IL-6 antibody for the treatment of rheumatoid arthritis with an October 30 FDA action date and is manufactured at Regeneron's antibody manufacturing facility in Rensselaer, New York, Tenthoff tells investors in a research note. The analyst points out that Regeneron reports Q3 results on November 4 and that he expects EYLEA sales of $835M. He maintains a Neutral rating on the shares with a $447 price target. Regeneron is trading down 3%, or $9.90, to $355.45 in early trading.
News For REGN;SNY From the Last 2 Days
SNY
Mar 27, 2024 | 06:16 EDT
Wells Fargo analyst Derek Archila raised the firm's price target on Annexon (ANNX) to $12 from $11 and keeps an Overweight rating on the shares. The firm believes the risk/reward remains favorable ahead of ANX005's Phase 3 data in GBS. Additionally, updates for ANX007 at ARVO, Phase 3 GBS data at PNS and read through from Sanofi's (SNY's) riliprubart in CIDP at AAN, all could offer upside for shares, Wells adds.